Incidence and Predictors of Post-TIPS Heart Failure in Patients With Cirrhosis

Sichuan University

Status: Enrolling

Conditions: Liver Cirrhosis; Transjugular Intrahepatic Portosystemic Shunt (TIPS); Heart Failure

Treatments: Procedure: TIPS

Study type: Observational

Funder types: Other

Identifiers

NCT05596253

HF-TIPS

Details and patient eligibility

About

The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

Full description

Hyperdynamic circulation is a common Phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(CCM). Transjugular intrahepatic portosystemic shunt (TIPS), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. However, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, TIPS further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Cirrhosis
2. TIPS is placed successfully
3. Agree to participate in the trial

Exclusion criteria

1. Non-cirrhotic portal hypertension
2. Previous TIPS or surgical shunt
3. Medium to severe pulmonary hypertension
4. Heart failure
5. End-stage renal disease requiring hemodialysis
6. Respiratory failure
7. Malignancies with a life expectancy of less than 6 months

Trial design

200 participants in 1 patient group

Patients with cirrhosis who underwent TIPS

Description:

Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.

Treatment:

Procedure: TIPS